Karyopharm Therapeutics (KPTI) Misses Q1 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/28/2026
Go back to Karyopharm Therapeutics (KPTI) Misses Q1 EPS by 1c
May 11, 2015 7:00 AM EDT
Positive Data in Difficult to Treat Cancers With Significant Unmet Need Further Supports Broad Clinical Development Campaign for Selinexor
Conference Call Scheduled for Today at 8:30 a.m. ET
NEWTON, Mass., May 11, 2015 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a clinical-stage pharmaceutical company, today reported financial results for the first quarter 2015 and commented on recent accomplishments and clinical development plans for selinexor, its lead product candidate.
"Karyopharm and its collaborators presented a comprehensive body of data across its oncology pipeline, including a total of twenty-one... More
May 11, 2015 7:00 AM EDT
Positive Data in Difficult to Treat Cancers With Significant Unmet Need Further Supports Broad Clinical Development Campaign for Selinexor
Conference Call Scheduled for Today at 8:30 a.m. ET
NEWTON, Mass., May 11, 2015 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a clinical-stage pharmaceutical company, today reported financial results for the first quarter 2015 and commented on recent accomplishments and clinical development plans for selinexor, its lead product candidate.
"Karyopharm and its collaborators presented a comprehensive body of data across its oncology pipeline, including a total of twenty-one... More
